AR115724A1 - PHARMACEUTICAL COMPOSITION CONTAINING A PEPTIDE - Google Patents

PHARMACEUTICAL COMPOSITION CONTAINING A PEPTIDE

Info

Publication number
AR115724A1
AR115724A1 ARP190101936A ARP190101936A AR115724A1 AR 115724 A1 AR115724 A1 AR 115724A1 AR P190101936 A ARP190101936 A AR P190101936A AR P190101936 A ARP190101936 A AR P190101936A AR 115724 A1 AR115724 A1 AR 115724A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
peptide
composition containing
composition
linaclotide
Prior art date
Application number
ARP190101936A
Other languages
Spanish (es)
Inventor
Jrg Hagedorn
George Shlieout
Jrn Lders
Kuldeep Bhokare
Den Akker Rob Van
Ronny Schulze
Christopher Rupp
Original Assignee
Abbott Laboratories Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories Gmbh filed Critical Abbott Laboratories Gmbh
Publication of AR115724A1 publication Critical patent/AR115724A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente se refiere a una composición farmacéutica estable para administración oral que comprende Linaclotide o sus sales farmacéuticamente aceptables y un portador. También se proporcionan métodos de preparación y uso de la composición. En particular, la composición se puede usar en el tratamiento de trastornos gastrointestinales, tales como constipación crónica y síndrome de intestino irritable.The present refers to a stable pharmaceutical composition for oral administration comprising Linaclotide or its pharmaceutically acceptable salts and a carrier. Methods of preparation and use of the composition are also provided. In particular, the composition can be used in the treatment of gastrointestinal disorders, such as chronic constipation and irritable bowel syndrome.

ARP190101936A 2018-07-09 2019-07-10 PHARMACEUTICAL COMPOSITION CONTAINING A PEPTIDE AR115724A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201811025533 2018-07-09

Publications (1)

Publication Number Publication Date
AR115724A1 true AR115724A1 (en) 2021-02-17

Family

ID=68165587

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101936A AR115724A1 (en) 2018-07-09 2019-07-10 PHARMACEUTICAL COMPOSITION CONTAINING A PEPTIDE

Country Status (6)

Country Link
AR (1) AR115724A1 (en)
BR (1) BR112021000201A2 (en)
CL (1) CL2021000022A1 (en)
CO (1) CO2021000158A2 (en)
MX (1) MX2021000312A (en)
WO (1) WO2020012243A2 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033427A1 (en) 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation of peptides with basic amino acids
JP5770629B2 (en) 2008-08-15 2015-08-26 アイアンウッド ファーマシューティカルズ インコーポレイテッド Stable solid formulation of GC-C receptor agonist polypeptide suitable for oral administration
EP2238979A1 (en) * 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Active pharmaceutical ingredient adsorbed on solid support
US9616097B2 (en) * 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US20140018307A1 (en) 2012-07-12 2014-01-16 Forest Laboratories Holdings Ltd. Linaclotide compositions
WO2016024291A1 (en) 2014-08-11 2016-02-18 Sun Pharmaceutical Industries Ltd. Linaclotide stable composition
EP3233059A1 (en) * 2014-12-19 2017-10-25 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide

Also Published As

Publication number Publication date
WO2020012243A3 (en) 2020-03-05
CL2021000022A1 (en) 2021-07-19
MX2021000312A (en) 2021-06-08
BR112021000201A2 (en) 2021-08-10
WO2020012243A2 (en) 2020-01-16
CO2021000158A2 (en) 2021-01-18

Similar Documents

Publication Publication Date Title
DOP2018000297A (en) DERIVATIVE OF GLUCAGON, CONJUGATE OF THE SAME, COMPOSITION THAT INCLUDES THE SAME AND THERAPEUTIC USE OF THE SAME
CL2019000431A1 (en) Tetrahydro-pyrido [3,4-b] indoles estrogen receptor modulators and uses thereof. (divisional application 201700814)
CO2019000945A2 (en) Modulators of the nmda spiro-lactam receptor and use thereof
CO2019000938A2 (en) Nmda spiro-lactam modulators and methods of use thereof
CO2019000943A2 (en) Modulators of the nmda spiro-lactam receptor and use thereof
CO2018013747A2 (en) Modulators of the spiro-lactam n-methyl-d-aspartate receptor and uses thereof
CO2019000944A2 (en) Modulators of the nmda spiro-lactam and bis-spiro-lactam receptor and use thereof
CO2019000941A2 (en) Modulators of the nmda spiro-lactam receptor and use thereof
CL2019002190A1 (en) Reduction of the viscosity of pharmaceutical formulations that comprise a therapeutic protein at a concentration of at least 70 mg / ml, where the therapeutic protein is not an antibody (divisional application 201700984)
AR096892A1 (en) A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA
DOP2016000254A (en) PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE.
AR111760A1 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS THROUGH INTRATUMORAL ADMINISTRATION
PE20130782A1 (en) PHARMACEUTICAL COMPOSITIONS CONSISTING OF PARACETAMOL AND THE PROCESS FOR THE PREPARATION OF THE SAME
CO7170181A2 (en) New composition of alfentanil for the treatment of acute pain
AR115724A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING A PEPTIDE
MX2013001279A (en) Pharmaceutical composition with a selective enzyme phosphodiesterase inhibitor in an oral gel form.
ECSP15033649A (en) A COMBINED MEDICINAL PRODUCT INCLUDING PHENYLEPHRINE AND PARACETAMOL
CO2018013792A2 (en) Dosing regimens of vortioxetine for the rapid onset of the antidepressant effect
DOP2019000233A (en) DROPROPIZIN IN COMBINATION WITH AMBROXOL IN THE PHARMACEUTICAL FORM OF SYRUP AND TABLET
EA201590732A1 (en) DISPENSABLE TABLET
AR105087A1 (en) METHODS FOR THE TREATMENT OF WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH THE BUPROPION AND TRAZODONA COMBINATION TREATMENT
PE20151431A1 (en) CONTROLLED-RELEASE LORAZEPAM FORMULATIONS
CO2019008347A2 (en) Quick release composition of cinitapride and simethicone and process to prepare it
GT201500333A (en) PHARMACEUTICAL SYNERGISTIC COMPOSITION OF TWO ANALGESICS WITH DIFFERENT FAMACOCINETIC PROFILE
CL2015003409A1 (en) Synergistic pharmaceutical composition of two analgesics with different pharmacokinetic profile